Vectus Biosystems Ltd
ASX:VBS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vectus Biosystems Ltd
Cash from Financing Activities
Vectus Biosystems Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vectus Biosystems Ltd
ASX:VBS
|
Cash from Financing Activities
AU$421.1k
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Financing Activities
$150.5m
|
CAGR 3-Years
65%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Financing Activities
-$2.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-18%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash from Financing Activities
AU$9.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Financing Activities
-AU$3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Financing Activities
AU$138.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
29%
|
CAGR 10-Years
32%
|
|
Vectus Biosystems Ltd
Glance View
Vectus Biosystems Ltd. operates as a drug discovery and development company. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm has developed treatments for fibrosis and high blood pressure, which include treatment for four of the diseases in the fibrotic franchise, namely heart, kidney, liver and lung disease. Its lead compound VB0004, which is aimed at treating the loss of functional tissue to fibrosis or scarring and high blood pressure. The firm has also developed a technology, Accugen for measuring the amount of Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Using its platform technology, the Company has constructed a library of approximately 200 small molecules with varying degrees of anti-hypertensive and anti-fibrotic properties. Accugen is developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions.
See Also
What is Vectus Biosystems Ltd's Cash from Financing Activities?
Cash from Financing Activities
421.1k
AUD
Based on the financial report for Dec 31, 2025, Vectus Biosystems Ltd's Cash from Financing Activities amounts to 421.1k AUD.
What is Vectus Biosystems Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-44%
The average annual Cash from Financing Activities growth rates for Vectus Biosystems Ltd have been -53% over the past three years , -44% over the past five years .
